An interventional study of Surgical Ablation and Cardioblate and Cryoflex hand held devices in Persistent Atrial Fibrillation and Longstanding Persistent Atrial Fibrillation, sponsored by Medtronic Cardiac Surgery. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Atrial Fibrillation by Medtronic — 8 open to participants now, 12 under way, none of them phase 3. Atrial Fibrillation · Medtronic.
Among the 84 studies in Atrial Fibrillation by Medtronic, this one is the 33rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2018, is one of 45 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 60th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 84 studies in Atrial Fibrillation by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic Cardiac Ablation Solutions · Sites in United States, Australia, Belgium and 3 more countries
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in United States, Canada, Korea, Republic of
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Australia, Belgium, Canada and 13 more countries
Ages 18+
Medtronic Cardiac Ablation Solutions · Sites in Czechia
Ages 18–75
Medtronic Cardiac Ablation Solutions · Sites in Lithuania
Ages 18–75
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 4 · Phase 4 15
First in 2000; this study’s year is marked. 8 started in 2018.
This study's planned enrollment of 160 is close to the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 155 across the 66 interventional studies, 777 across the 18 observational. Of the 70 that completed or were terminated, 39 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Surgery, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
3 of the studies in Atrial Fibrillation by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT06578104Medtronic Cardiac Ablation SolutionsPULSED AF Post-Approval Study | 2027-04-30 |
| NCT07308847Medtronic Cardiac Ablation SolutionsHorizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Atrial Fibrillation by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal atrial fibrillation (AF).
This is a multi-center, single-arm, prospective, non-randomized, interventional study. A maximum of 160 subjects will be treated at up to 25 centers in the United States (US). The study will include male and female patients with a history of non-paroxysmal atrial fibrillation who are undergoing concomitant cardiac surgery. Subjects will be followed and assessed after procedure and for 12 months.
The purpose of this study is to evaluate the safety and effectiveness of the Cardioblate Surgical Ablation iRF and CryoFlex hand held devices to support an indication expansion to include treatment of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) to the product labeling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concomitant indication for non-emergent open-heart surgery, eg,
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a history of persistent atrial fibrillation and long-standing persistent atrial fibrillation (non-paroxysmal atrial fibrillation) who are undergoing concomitant cardiac surgery
Procedure: Surgical Ablation · Device: Cardioblate and Cryoflex hand held devices
In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
The Cardioblate hand held devices consist of the Cardioblate iRF and Cryoflex surgical ablation devices.
Composite acute major adverse event rate
Composite acute major adverse event rate including: Atrial tears, Esophageal injury, Excessive bleeding, Mediastinitis, Myocardial infarction (MI), Pulmonary embolism, Peripheral arterial embolism, Stroke, Transient ischemic attacks (TIA), Death.
Time frame: 30-days post-procedure or hospital discharge (whichever is longer)
Freedom from Atrial Fibrillation (AF)/Atrial Flutter (AFL)/Atrial Tachycardia (AT)
Freedom from AF/AFL/AT of 30 seconds or greater duration on Holter, and 10 seconds on 12-lead ECG after removal from antiarrhythmic drug (AAD) therapy.
Time frame: 6-months post-procedure to 12-months post-procedure
Composite acute major adverse event rate (Safety)
Composite acute major adverse event rate at 6 months post-procedure (as defined above)
Time frame: 6-months post-procedure
Composite acute major adverse event rate (Safety)
Composite acute major adverse event rate at 12 months post-procedure (as defined above)
Time frame: 12-months post-procedure
Percentage of new permanent pacemaker implantation (Safety)
Percentage of new permanent pacemaker implantation presented by indication
Time frame: 12-months post-procedure
Acute procedural success (Efficacy)
Acute procedural success (pulmonary vein isolation)
Time frame: During index procedure
Freedom from AF/AFL/AT after removal of AAD therapy through 6-months post-procedure (Efficacy)
Freedom from AF/AFL/AT of 30 seconds or greater duration after removal from AAD therapy as assessed from the end of the 3-month blanking period through 6 months post-procedure
Time frame: 6-months post-procedure
Freedom from AF/AFL/AT through 6-months post-procedure (Efficacy)
Freedom from AF/AFL/AT of 30 seconds or greater duration regardless of AAD status through 6 months post-procedure
Time frame: 6-months post-procedure
Freedom from AF/AFL/AT through 12-months post-procedure (Efficacy)
Freedom from AF/AFL/AT of 30 seconds or greater duration regardless of AAD status through 12 months post-procedure
Time frame: 12-months post-procedure
Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Quality of Life Score over time (Efficacy)
Characterization of quality of life scores over time as assessed by AFEQT questionnaire. AFEQT overall score ranges from 0-100. Zero corresponds to complete disability and 100 corresponds to no disability. The means, medians, standard deviations, interquartile ranges, minima, and maxima will be provided for the quality of life scores by visit interval.
Time frame: 12-months post-procedure
SF-12 Health Survey (SF-12) Quality of Life Score over time (Efficacy)
Characterization of quality of life scores over time as assessed by SF-12 questionnaire. SF-12 overall score ranges from 0-100. Zero indicates the lowest level of health measured by the scale and 100 indicates the highest level of health. The means, medians, standard deviations, interquartile ranges, minima, and maxima will be provided for the quality of life scores by visit interval.
Time frame: 12-months post-procedure
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Ran from Nov 2018 to primary completion in Oct 2024, 70 months.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 70 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.